Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

NCT04813861 | Completed

• 1 other identifier: 2020-PI199-99
• Study Type: observational
• Target: 57
• Locations: 1 country
• Sites: 1

Brief Summary

Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot be considered in case of an HCC classified in an intermediate stage, a Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial response or the treatment of some lesions of a multifocal HCC, a combined treatment by stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may be initiated in accordance with a decision of the multidisciplinary consultation meeting. The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK after downstaging with TACE.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma; Transarterial Chemoembolization; Stereotactic body radiotherapy; Radiofrequency Ablation; Microwave Ablation

Outcome Measures

Primary Outcomes (1)

• Lesion Response

  Lesion response after combined treatment

  4-6 weeks after BWA or RFA or 3-6 months after CK

Secondary Outcomes (1)

• Delayed Lesion Response

  1 year after BWA, RFA or CK

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who have been treated for HCC by TACE, followed by additional treatment with RFA, MWA or CK in the following year, between January 2010 and December 2020 by Nancy Regional University Hospital (TACE, RFA, MWA) and Lorraine Institute of Cancer (CK)

You may qualify if:

• a HCC treated by TACE followed by RFA, MWA and/or CK
• from 01/2010 to 12/2020
• treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)

You may not qualify if:

• Combined treatment over one year following the last TACE
• No baseline, in between or after combined treatment imaging
• Lesion appeared after TACE treatment

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

CHRU de Nancy

Nancy, 54000, France

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: March 21, 2021
• First Posted: March 24, 2021
• Study Start: January 4, 2010
• Primary Completion: December 1, 2019
• Study Completion: March 1, 2021
• Last Updated: March 24, 2021

Record last verified: 2021-03

Locations

FR (1)